Equities analysts predict that Xylem Inc (NYSE:XYL) will post sales of $1.17 billion for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Xylem’s earnings, with the highest sales estimate coming in at $1.19 billion and the lowest estimate coming in at $1.14 billion. Xylem reported sales of $1.30 billion during the same quarter last year, which indicates a negative year-over-year growth rate of 10%. The business is scheduled to issue its next quarterly earnings results on Thursday, October 29th.
On average, analysts expect that Xylem will report full year sales of $4.74 billion for the current financial year, with estimates ranging from $4.69 billion to $4.78 billion. For the next fiscal year, analysts anticipate that the company will report sales of $5.07 billion, with estimates ranging from $4.89 billion to $5.24 billion. Zacks’ sales averages are a mean average based on a survey of research firms that follow Xylem.
Xylem (NYSE:XYL) last announced its earnings results on Thursday, July 30th. The industrial products company reported $0.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.39 by $0.01. Xylem had a return on equity of 14.72% and a net margin of 5.09%. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.15 billion.
Several equities research analysts recently commented on the company. Royal Bank of Canada reissued a “buy” rating on shares of Xylem in a report on Sunday. Credit Suisse Group boosted their target price on Xylem from $62.00 to $69.00 and gave the stock an “underperform” rating in a report on Friday, July 31st. Robert W. Baird lifted their price target on shares of Xylem from $71.00 to $74.00 and gave the stock a “neutral” rating in a research report on Friday, June 19th. Oppenheimer restated a “hold” rating on shares of Xylem in a research report on Thursday, July 30th. Finally, Janney Montgomery Scott lifted their price target on shares of Xylem from $63.00 to $67.00 and gave the stock a “neutral” rating in a research report on Wednesday, June 3rd. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and three have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $70.64.
In other Xylem news, SVP Colin R. Sabol sold 2,066 shares of Xylem stock in a transaction on Wednesday, July 15th. The shares were sold at an average price of $75.00, for a total transaction of $154,950.00. Following the completion of the sale, the senior vice president now owns 31,185 shares of the company’s stock, valued at approximately $2,338,875. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP David Flinton sold 1,008 shares of Xylem stock in a transaction on Monday, August 24th. The shares were sold at an average price of $80.86, for a total transaction of $81,506.88. Following the sale, the senior vice president now directly owns 25,757 shares of the company’s stock, valued at approximately $2,082,711.02. The disclosure for this sale can be found here. Insiders own 1.01% of the company’s stock.
Several large investors have recently modified their holdings of the business. Victory Capital Management Inc. lifted its stake in shares of Xylem by 76.3% in the 1st quarter. Victory Capital Management Inc. now owns 1,907,364 shares of the industrial products company’s stock valued at $124,226,000 after purchasing an additional 825,441 shares during the last quarter. AE Wealth Management LLC bought a new position in shares of Xylem during the 1st quarter worth about $279,000. Oppenheimer Asset Management Inc. increased its holdings in shares of Xylem by 7.9% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 35,683 shares of the industrial products company’s stock worth $2,324,000 after purchasing an additional 2,617 shares during the period. First Allied Advisory Services Inc. increased its holdings in shares of Xylem by 43.9% during the 1st quarter. First Allied Advisory Services Inc. now owns 3,797 shares of the industrial products company’s stock worth $247,000 after purchasing an additional 1,158 shares during the period. Finally, Cambridge Investment Research Advisors Inc. increased its holdings in shares of Xylem by 24.4% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 9,470 shares of the industrial products company’s stock worth $617,000 after purchasing an additional 1,859 shares during the period. 84.92% of the stock is owned by institutional investors.
Shares of NYSE:XYL opened at $85.21 on Thursday. Xylem has a 12 month low of $54.62 and a 12 month high of $89.34. The stock has a market cap of $15.33 billion, a price-to-earnings ratio of 61.30, a PEG ratio of 4.57 and a beta of 1.07. The stock’s 50 day moving average price is $79.67 and its 200 day moving average price is $70.82. The company has a debt-to-equity ratio of 1.06, a current ratio of 2.40 and a quick ratio of 1.97.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 24th. Shareholders of record on Thursday, August 27th will be given a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a yield of 1.22%. The ex-dividend date of this dividend is Wednesday, August 26th. Xylem’s payout ratio is 34.44%.
Xylem Company Profile
Xylem Inc engages in the design, manufacture, and servicing of engineered products and solutions for the water and wastewater applications. It operates in three segments: Water Infrastructure, Applied Water, and Measurement & Control Solutions. The Water Infrastructure segment offers various products, including water and wastewater pumps; controls and systems; filtration, disinfection, and biological treatment equipment; and mobile dewatering equipment under the Flygt, Godwin, Wedeco, Sanitaire, and Leopold names for the transportation and treatment of water.
Further Reading: How to find the components of the quick ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xylem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xylem and related companies with MarketBeat.com's FREE daily email newsletter.